|
1
|
Nakamura H and Saji H: Worldwide trend of
increasing primary adenocarcinoma of the lung. Surg Today.
44:1004–1012. 2014.
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015.
|
|
3
|
Abbas AK, Lichtman AH and Pillai S:
Cellular and Molecular Immunology. 8th edition. Elsevier Saunders;
Philadelphia, PA: pp. 109–220. 2015
|
|
4
|
Vesely MD, Kershaw MH, Schreiber RD and
Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev
Immunol. 29:235–271. 2011.
|
|
5
|
June CH: Principles of adoptive T cell
cancer therapy. J Clin Invest. 117:1204–1212. 2007.
|
|
6
|
Turtle CJ and Riddell SR: Artificial
antigen-presenting cells for use in adoptive immunotherapy. Cancer
J. 16:374–381. 2010.
|
|
7
|
Roulois D, Grégoire M and Fonteneau JF:
MUC1-specific cytotoxic T lymphocytes in cancer therapy: Induction
and challenge. Biomed Res Int. 2013:8719362013.
|
|
8
|
Singh R and Bandyopadhyay D: MUC1: A
target molecule for cancer therapy. Cancer Biol Ther. 6:481–486.
2007.
|
|
9
|
Madurga S, Belda I, Llorà X and Giralt E:
Design of enhanced agonists through the use of a new virtual
screening method: Application to peptides that bind class I major
histocompatibility complex (MHC) molecules. Protein Sci.
14:2069–2079. 2005.
|
|
10
|
Koido S, Enomoto Y, Apostolopoulos V and
Gong J: Tumor regression by CD4 T-cells primed with dendritic/tumor
fusion cell vaccines. Anticancer Res. 34:3917–3924. 2014.
|
|
11
|
Ninkovic T, Kinarsky L, Engelmann K,
Pisarev V, Sherman S, Finn OJ and Hanisch FG: Identification of
O-glycosylated decapeptides within the MUC1 repeat domain as
potential MHC class I (A2) binding epitopes. Mol Immunol.
47:131–140. 2009.
|
|
12
|
Bossi G, Gerry AB, Paston SJ, Sutton DH,
Hassan NJ and Jakobsen BK: Examining the presentation of
tumor-associated antigens on peptide-pulsed T2 cells.
Oncoimmunology. 2:e268402013.
|
|
13
|
Jaramillo A, Narayanan K, Campbell LG,
Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR and
Mohanakumar T: Recognition of HLA-A2-restricted
mammaglobin-A-derived epitopes by CD8+ cytotoxic T
lymphocytes from breast cancer patients. Breast Cancer Res Treat.
88:29–41. 2004.
|
|
14
|
Sobin LH, Gospodarowicz MK and Witterkind
C: The TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; Oxford: pp. 211–230. 2009
|
|
15
|
Apostolopoulos V, Yu M, Corper AL, Li W,
McKenzie IF, Teyton L, Wilson IA and Plebanski M: Crystal structure
of a non-canonical high affinity peptide complexed with MHC class
I: A novel use of alternative anchors. J Mol Biol. 318:1307–1316.
2002.
|
|
16
|
Bednarek MA, Sauma SY, Gammon MC, Porter
G, Tamhankar S, Williamson AR and Zweerink HJ: The minimum peptide
epitope from the influenza virus matrix protein. Extra and
intracellular loading of HLA-A2. J Immunol. 147:4047–4053.
1991.
|
|
17
|
Fremont DH, Stura EA, Matsumura M,
Peterson PA and Wilson IA: Crystal structure of an
H-2Kb-ovalbumin peptide complex reveals the interplay of
primary and secondary anchor positions in the major
histocompatibility complex binding groove. Proc Natl Acad Sci USA.
92:2479–2483. 1995.
|
|
18
|
Lundegaard C, Lamberth K, Harndahl M, Buus
S, Lund O and Nielsen M: NetMHC-3.0: Accurate web accessible
predictions of human, mouse and monkey MHC class I affinities for
peptides of length 8–11. Nucleic Acids Res. 36:W509–W512. 2008.
|
|
19
|
Bøyum A: Isolation of lymphocytes,
granulocytes and macrophages. Scand J Immunol. 5(Suppl 5): 9–15.
1976.
|
|
20
|
Luft T, Rizkalla M, Tai TY, Chen Q,
MacFarlan RI, Davis ID, Maraskovsky E and Cebon J: Exogenous
peptides presented by transporter associated with antigen
processing (TAP)-deficient and TAP-competent cells: Intracellular
loading and kinetics of presentation. J Immunol. 167:2529–2537.
2001.
|
|
21
|
Tan J, Tang X and Xie T: Comparison of HLA
class I typing by serology with DNA typing in a Chinese population.
Transplant Proc. 32:1859–1861. 2000.
|
|
22
|
Manders EMM, Verbeek JF and Aten JA:
Measurement of co-localization of objects in dual-colour confocal
images. J Microsc. 169:375–382. 1993.
|
|
23
|
Lyons AB and Parish CR: Determination of
lymphocyte division by flow cytometry. J Immunol Methods.
171:131–137. 1994.
|
|
24
|
Suda K and Mitsudomi T: Successes and
limitations of targeted cancer therapy in lung cancer. Prog Tumor
Res. 41:62–77. 2014.
|
|
25
|
Wangari-Talbot J and Hopper-Borge E: Drug
resistance mechanisms in non-small cell lung carcinoma. J Can Res
Updates. 2:265–282. 2013.
|
|
26
|
Dudley ME and Rosenberg SA:
Adoptive-cell-transfer therapy for the treatment of patients with
cancer. Nat Rev Cancer. 3:666–675. 2003.
|
|
27
|
Disis ML: Immune regulation of cancer. J
Clin Oncol. 28:4531–4538. 2010.
|
|
28
|
Skånland SS, Moltu K, Berge T, Aandahl EM
and Taskén K: T-cell co-stimulation through the CD2 and CD28
co-receptors induces distinct signalling responses. Biochem J.
460:399–410. 2014.
|
|
29
|
Perica K, Kosmides AK and Schneck JP:
Linking form to function: Biophysical aspects of artificial antigen
presenting cell design. Biochim Biophys Acta. 1853:781–790.
2015.
|
|
30
|
Dittmann J, Keller-Matschke K, Weinschenk
T, Kratt T, Heck T, Becker HD, Stevanović S, Rammensee HG and
Gouttefangeas C: CD8+ T-cell response against
MUC1-derived peptides in gastrointestinal cancer survivors. Cancer
Immunol Immunother. 54:750–758. 2005.
|
|
31
|
Gückel B, Rentzsch C, Nastke MD, Marmé A,
Gruber I, Stevanović S, Kayser S and Wallwiener D: Pre-existing
T-cell immunity against mucin-1 in breast cancer patients and
healthy volunteers. J Cancer Res Clin Oncol. 132:265–274. 2006.
|
|
32
|
Kokowski K, Harnack U, Dorn DC and Pecher
G: Quantification of the CD8+ T cell response against a
mucin epitope in patients with breast cancer. Arch Immunol Ther Exp
(Warsz). 56:141–145. 2008.
|
|
33
|
Choi C, Witzens M, Bucur M, Feuerer M,
Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H and
Beckhove P: Enrichment of functional CD8 memory T cells specific
for MUC1 in bone marrow of patients with multiple myeloma. Blood.
105:2132–2134. 2005.
|
|
34
|
Hamaï A, Benlalam H, Meslin F, Hasmim M,
Carré T, Akalay I, Janji B, Berchem G, Noman MZ and Chouaib S:
Immune surveillance of human cancer: If the cytotoxic T-lymphocytes
play the music, does the tumoral system call the tune? Tissue
Antigens. 75:1–8. 2010.
|
|
35
|
Finn OJ: Cancer immunology. N Engl J Med.
358:2704–2715. 2008.
|
|
36
|
Hwang I and Nguyen N: Mechanisms of
tumor-induced T cell immune suppression and therapeutics to counter
those effects. Arch Pharm Res. 38:1415–1433. 2015.
|
|
37
|
Quinlin IS, Burnside JS, Dombrowski KE,
Phillips CA, Dolby N and Wright SE: Context of MUC1 epitope:
Immunogenicity. Oncol Rep. 17:453–456. 2007.
|
|
38
|
Hamel ME, Noteboom E and Kruisbeek AM:
Non-responsiveness of antigen-experienced CD4 T cells reflects more
stringent co-stimulatory requirements. Immunology. 93:366–375.
1998.
|
|
39
|
Phillips JD, Knab LM, Blatner NR, Haghi L,
DeCamp MM, Meyerson SL, Heiferman MJ, Heiferman JR, Gounari F,
Bentrem DJ, et al: Preferential expansion of pro-inflammatory Tregs
in human non-small cell lung cancer. Cancer Immunol Immunother.
64:1185–1191. 2015.
|
